Pure Bioscience, Inc. (PURE) stock
PUREOTCMiscellaneous Chemical ProductsFiscal year ends July 31
$0.07−0.01 (-12.10%)
Close on Oct 19, 2026Market cap $8.67MP/E –Yield –
Pure Bioscience r&d expenses
Research and development expenses are spending on new products and technology.
Pure Bioscience's R&D Expenses for the twelve months ending Jul 31, 2026 was $332.00K, up 5.1% year over year. For fiscal 2026 it was $332.00K, up 5.1% from the year before. Over ten years it grew -9.8% a year on average. The highest annual figure on record is $2.18M in fiscal 2011.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jul 31, 2026 | $332.00K | +5.1% |
| FY2025 | Jul 31, 2025 | $316.00K | +4.6% |
| FY2024 | Jul 31, 2024 | $302.00K | +1.7% |
| FY2023 | Jul 31, 2023 | $297.00K | -6.9% |
| FY2022 | Jul 31, 2022 | $319.00K | -5.9% |
| FY2021 | Jul 31, 2021 | $339.00K | +5.3% |
| FY2020 | Jul 31, 2020 | $322.00K | -9.0% |
| FY2019 | Jul 31, 2019 | $354.00K | -22.9% |
| FY2018 | Jul 31, 2018 | $459.00K | -41.1% |
| FY2017 | Jul 31, 2017 | $779.00K | -16.0% |
| FY2016 | Jul 31, 2016 | $927.00K | +17.3% |
| FY2015 | Jul 31, 2015 | $790.00K | -23.4% |
| FY2014 | Jul 31, 2014 | $1.03M | -11.7% |
| FY2013 | Jul 31, 2013 | $1.17M | -37.3% |
| FY2012 | Jul 31, 2012 | $1.86M | -14.5% |
| FY2011 | Jul 31, 2011 | $2.18M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jul 31, 2026 | $93.00K | +27.4% |
| Q3 FY2026CQ1 2026 | Apr 30, 2026 | $79.00K | -13.2% |
| Q2 FY2026CQ4 2025 | Jan 31, 2026 | $74.00K | -8.6% |
| Q1 FY2026CQ3 2025 | Oct 31, 2025 | $86.00K | +21.1% |
| Q4 FY2025CQ2 2025 | Jul 31, 2025 | $73.00K | +5.8% |
| Q3 FY2025CQ1 2025 | Apr 30, 2025 | $91.00K | +18.2% |
| Q2 FY2025CQ4 2024 | Jan 31, 2025 | $81.00K | +6.6% |
| Q1 FY2025CQ3 2024 | Oct 31, 2024 | $71.00K | -11.3% |
| Q4 FY2024CQ2 2024 | Jul 31, 2024 | $69.00K | -1.4% |
| Q3 FY2024CQ1 2024 | Apr 30, 2024 | $77.00K | +4.1% |
| Q2 FY2024CQ4 2023 | Jan 31, 2024 | $76.00K | +1.3% |
| Q1 FY2024CQ3 2023 | Oct 31, 2023 | $80.00K | +2.6% |
| Q4 FY2023CQ2 2023 | Jul 31, 2023 | $70.00K | +9.4% |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | $74.00K | -30.8% |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | $75.00K | -7.4% |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | $78.00K | +16.4% |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | $64.00K | -13.5% |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | $107.00K | +20.2% |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | $81.00K | -12.9% |
| Q1 FY2022CQ3 2021 | Oct 31, 2021 | $67.00K | -19.3% |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | $74.00K | -22.1% |
| Q3 FY2021CQ1 2021 | Apr 30, 2021 | $89.00K | +4.7% |
| Q2 FY2021CQ4 2020 | Jan 31, 2021 | $93.00K | +55.0% |
| Q1 FY2021CQ3 2020 | Oct 31, 2020 | $83.00K | +1.2% |
| Q4 FY2020CQ2 2020 | Jul 31, 2020 | $95.00K | -9.5% |
| Q3 FY2020CQ1 2020 | Apr 30, 2020 | $85.00K | 0.0% |
| Q2 FY2020CQ4 2019 | Jan 31, 2020 | $60.00K | -10.4% |
| Q1 FY2020CQ3 2019 | Oct 31, 2019 | $82.00K | -15.5% |
| Q4 FY2019CQ2 2019 | Jul 31, 2019 | $105.00K | +34.6% |
| Q3 FY2019CQ1 2019 | Apr 30, 2019 | $85.00K | -27.4% |
| Q2 FY2019CQ4 2018 | Jan 31, 2019 | $67.00K | -44.2% |
| Q1 FY2019CQ3 2018 | Oct 31, 2018 | $97.00K | -32.6% |
| Q4 FY2018CQ2 2018 | Jul 31, 2018 | $78.00K | -17.9% |
| Q3 FY2018CQ1 2018 | Apr 30, 2018 | $117.00K | -47.3% |
| Q2 FY2018CQ4 2017 | Jan 31, 2018 | $120.00K | -43.9% |
| Q1 FY2018CQ3 2017 | Oct 31, 2017 | $144.00K | -41.9% |
| Q4 FY2017CQ2 2017 | Jul 31, 2017 | $95.00K | – |
| Q3 FY2017CQ1 2017 | Apr 30, 2017 | $222.00K | – |
| Q2 FY2017CQ4 2016 | Jan 31, 2017 | $214.00K | – |
| Q1 FY2017CQ3 2016 | Oct 31, 2016 | $248.00K | – |
See a number that looks wrong?